arrow
M

Melek Karakurt Eryılmaz

Necmettin Erbakan University
H指数:11
被引数:378

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The efficacy of nivolumab does not increase in current smokers with metastatic non-small cell lung cancer: multicenter, retrospective, and observational study

纳武利尤单抗在吸烟的转移性非小细胞肺癌患者中的疗效未增加:多中心、回顾性及观察性研究

2026-11-170
OA
Remnant cholesterol inflammatory index for predicting pathological complete response to neoadjuvant therapy in breast cancer: A multicenter external validation study

残余胆固醇炎症指数预测乳腺癌新辅助治疗病理完全缓解:一项多中心外部验证研究

Breast
IF7.9
2026-09-220
OA
Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

晚期胸腺癌二线治疗的实际疗效:一项多中心土耳其肿瘤学组(TOG)研究

2026-08-270
OA
Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

三阴性乳腺癌新辅助化疗患者的CPS-EG评分的预后意义

Cancers
IF4.4
2026-08-180
OA
Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study

在EGFR突变NSCLC发生SCLC转化后,联合免疫疗法与化疗可能改善生存:一项多中心真实世界研究

2026-08-010
PRE
Development and internal validation of the CLIP-M score for advanced mucosal malignant melanoma: exploratory prognostic stratification and comparative assessment with the RMH score

CLIP-M评分在进展期黏膜黑色素瘤中的开发与内部验证:探索性预后分层及与RMH评分的比较评估

2026-05-220
OAAI
Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

评估以贝伐珠单抗为基础的治疗在复发性原发性脑肿瘤中的有效性和耐受性:一项多中心真实世界土耳其肿瘤学会(TOG)研究

2026-02-140
OAAI
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

brigatinib 在晚期ALK阳性NSCLC中的真实世界有效性与安全性:土耳其肿瘤学组进行的一项全国多中心研究

2026-02-110
PRE
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study

质子泵抑制剂对转移性非小细胞肺癌中纳武利尤单抗疗效的影响:一项多中心真实世界研究

2026-01-200
PRE
Survival outcomes and recurrence patterns of early-stage HER2-positive breast cancer patients on adjuvant T-DM1 treatment: Turkish Oncology Group (TOG) Study

早期HER2阳性乳腺癌患者接受辅助T-DM1治疗的生存结局与复发模式:土耳其肿瘤学组(TOG)研究

2025-12-010
PRE
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

靶向疗法在肺鳞状细胞癌转移中的疗效:一项土耳其肿瘤学组多中心研究

2025-12-010
PRE
Chronic kidney disease and denosumab in metastatic bone disease: A multicenter Turkish cohort study on severe hypocalcemia, skeletal events, and survival

慢性肾病与地诺单抗在骨转移性疾病中的应用:一项关于严重低钙血症、骨骼事件和生存情况的多中心土耳其队列研究

2025-11-210
OAAI
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

曲拉妥单抗(sacituzumab govitecan)在伴有转移性或局部晚期不可切除的三阴性乳腺癌患者中的真实世界有效性与安全性:土耳其肿瘤学组(Turkish Oncology Group)开展的一项多中心研究

2025-10-280
PRE